Goldline Pharmaceutical IPO GMP History & Trend
Goldline Pharmaceutical IPO GMP Trend Chart
Goldline Pharmaceutical IPO GMP Trend Analysis
Goldline Pharmaceutical IPO Grey Market Premium (GMP) has been tracked for 9 days since the IPO was announced. The GMP started at ₹0 and currently stands at ₹17, showing a positive movement of ₹17 over this period.
At the current GMP of ₹17, the expected listing price is ₹60, which represents a premium of 39.5% over the upper price band of ₹43. The highest GMP recorded during this tracking period was ₹25, while the lowest was ₹0.
In the last 3 days, the GMP has remained stable, suggesting that the market has priced in the expected listing gains and sentiment is holding steady. This recent flat trend is an important signal for investors evaluating whether to apply for or hold their position in this IPO.
For retail investors who applied at the upper price band of ₹43, the current GMP of ₹17 translates to an estimated profit of ₹51,000 per lot (3000 shares) on listing day. The total investment per lot at the upper band is ₹129,000, making the expected return +39.5% on the investment amount.
The IPO subscription data shows total subscription of 840.81x, with Qualified Institutional Buyers (QIB) at 180.22x, Non-Institutional Investors (NII/HNI) at 1,662.39x, and Retail Individual Investors at 881.15x. The exceptionally strong QIB subscription of 180.22x indicates significant institutional confidence in the company fundamentals, which historically correlates with strong listing performance.
From a valuation perspective, Goldline Pharmaceutical IPO is priced at a P/E ratio of 10.01x based on an EPS of ₹4.10. This is a relatively attractive valuation, suggesting the shares may have room for appreciation post-listing. The current GMP of ₹17 suggests the market believes the IPO is fairly or attractively priced at this P/E level.
Grey Market Premium is an unofficial indicator of market sentiment and is not regulated by SEBI. GMP values change daily based on demand, supply, and overall market conditions. Investors should not rely solely on GMP for making investment decisions. Always review the company's financials, business model, and Red Herring Prospectus (RHP) before applying. Consult a SEBI-registered financial advisor for personalized investment guidance.
Goldline Pharmaceutical IPO — Daily GMP History
| Date | GMP (₹) | Est. Listing (₹) | Listing Gain % | Sauda Rate (₹) | Change |
|---|---|---|---|---|---|
| 18 May 2026 | +₹17 | ₹60 | +39.5% | ₹38,800 | - |
| 16 May 2026 | +₹17 | ₹60 | +39.5% | ₹36,600 | - |
| 15 May 2026 | +₹17 | ₹60 | +39.5% | ₹36,600 | - |
| 14 May 2026 | +₹25 | ₹68 | +58.1% | ₹56,500 | ▲ +₹8 |
| 13 May 2026 | +₹17 | ₹60 | +39.5% | ₹38,500 | ▼ ₹-8 |
| 12 May 2026 | +₹17 | ₹60 | +39.5% | ₹38,000 | - |
| 11 May 2026 | +₹15 | ₹58 | +34.9% | ₹34,000 | ▼ ₹-2 |
| 09 May 2026 | +₹5 | ₹48 | +11.6% | ₹12,000 | ▼ ₹-10 |
| 08 May 2026 | ₹0 | ₹43 | 0% | - | ▼ ₹-5 |
What is IPO GMP (Grey Market Premium)?
IPO Grey Market Premium (GMP) is the unofficial price at which IPO shares trade in the grey market before their listing on NSE or BSE. It reflects investor sentiment and expected demand for the IPO. A positive GMP suggests the IPO may list above its issue price, while a negative GMP indicates potential listing below issue price.
GMP for Goldline Pharmaceutical IPO is tracked daily from the time the IPO is announced until the listing date. The GMP trend helps investors gauge changing market sentiment — a rising GMP indicates growing demand, while a falling GMP may signal weakening interest.
How to Read the GMP Trend Chart
- Rising trend (green): Increasing demand and positive sentiment — investors are willing to pay higher premiums for the shares.
- Falling trend: Decreasing demand — could be due to market correction, overvaluation concerns, or better alternatives available.
- Flat trend: Stable sentiment — the market has priced in the expected listing gain.
- GMP near zero: The IPO is expected to list close to its issue price — minimal grey market interest.
Frequently Asked Questions
What is Goldline Pharmaceutical IPO GMP today?
As of 01 Jun 2026, the Grey Market Premium for Goldline Pharmaceutical IPO is ₹17 per share. This suggests an expected listing at ₹60, which is a 39.5% premium over the issue price of ₹43. GMP is updated daily on GmpUpdates.
Is Goldline Pharmaceutical IPO GMP increasing or decreasing?
Over the tracked period of 9 days, Goldline Pharmaceutical IPO GMP has increased by ₹17. The highest GMP was ₹25 and lowest was ₹0. Check the trend chart above for the complete daily movement.
Should I invest based on GMP?
GMP should not be the sole factor in your investment decision. While it indicates market sentiment, actual listing performance depends on multiple factors including company fundamentals, valuations, market conditions on listing day, and institutional demand. Always review the Red Herring Prospectus (RHP) and consult a SEBI-registered financial advisor before investing.